Viridian Therapeutics Inc. reported its third quarter 2025 financial results and recent business progress. The company completed a set of financing transactions in October 2025, securing access to up to $889 million in potential capital through equity, royalty, and credit arrangements. Viridian also amended its credit facility with Hercules Capital, providing up to $300 million in available capital and extending the interest-only payment period. The company announced the successful submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration for veligrotug in thyroid eye disease (TED), with preparations underway for a potential U.S. commercial launch in mid-2026, pending approval under a Priority Review timeline. Topline data readouts for subcutaneous VRDN-003 were accelerated, with REVEAL-1 data expected in Q1 2026 and REVEAL-2 in Q2 2026, after both studies exceeded enrollment targets. Viridian stated that its current cash, anticipated near-term royalty milestones, and expected commercial revenues from veligrotug and VRDN-003, if approved, are projected to fund its business plans through profitability.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Viridian Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-265711), on November 05, 2025, and is solely responsible for the information contained therein.
Comments